Terms: = Prostate cancer AND RANBP2, NUP358, 5903, ENSG00000153201, P49792, TRP1, TRP2
13 results:
1. Oncogenic potential of nucleoporins in non-hematological cancers: recent update beyond chromosome translocation and gene fusion.
Roy A; Narayan G
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2901-2910. PubMed ID: 31654122
[TBL] [Abstract] [Full Text] [Related]
2. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Takayama KI; Suzuki T; Tanaka T; Fujimura T; Takahashi S; Urano T; Ikeda K; Inoue S
Oncogene; 2018 Apr; 37(16):2165-2180. PubMed ID: 29379164
[TBL] [Abstract] [Full Text] [Related]
3. Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.
Ashikari D; Takayama K; Tanaka T; Suzuki Y; Obinata D; Fujimura T; Urano T; Takahashi S; Inoue S
Oncogene; 2017 Nov; 36(45):6272-6281. PubMed ID: 28692047
[TBL] [Abstract] [Full Text] [Related]
4. Stratifying prostate cancer patients by relative lymph node involvement: population- and modeling-based study.
Poleszczuk JT; Johnstone PA; Enderling H
Cancer Med; 2016 Aug; 5(8):1850-5. PubMed ID: 27227813
[TBL] [Abstract] [Full Text] [Related]
5. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract] [Full Text] [Related]
6. Apoptotic death of prostate cancer cells by a gonadotropin-releasing hormone-II antagonist.
Park S; Han JM; Cheon J; Hwang JI; Seong JY
PLoS One; 2014; 9(6):e99723. PubMed ID: 24926857
[TBL] [Abstract] [Full Text] [Related]
7. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity.
Yu X; Guo C; Yi H; Qian J; Fisher PB; Subjeck JR; Wang XY
Cancer Res; 2013 Apr; 73(7):2093-103. PubMed ID: 23333935
[TBL] [Abstract] [Full Text] [Related]
8. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells.
Kim DK; Yang JS; Maiti K; Hwang JI; Kim K; Seen D; Ahn Y; Lee C; Kang BC; Kwon HB; Cheon J; Seong JY
Cancer Res; 2009 Feb; 69(3):923-31. PubMed ID: 19176390
[TBL] [Abstract] [Full Text] [Related]
9. Mst1, ranbp2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
Renner O; Fominaya J; Alonso S; Blanco-Aparicio C; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1418-25. PubMed ID: 17372272
[TBL] [Abstract] [Full Text] [Related]
10. An autologous oral DNA vaccine protects against murine melanoma.
Xiang R; Lode HN; Chao TH; Ruehlmann JM; Dolman CS; Rodriguez F; Whitton JL; Overwijk WW; Restifo NP; Reisfeld RA
Proc Natl Acad Sci U S A; 2000 May; 97(10):5492-7. PubMed ID: 10779556
[TBL] [Abstract] [Full Text] [Related]
11. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
[TBL] [Abstract] [Full Text] [Related]
12. Tissue specific promoters in targeting systemically delivered gene therapy.
Hart IR
Semin Oncol; 1996 Feb; 23(1):154-8. PubMed ID: 8607025
[TBL] [Abstract] [Full Text] [Related]
13. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract] [Full Text] [Related]
